According to @CNBC, citing Bloomberg News, Novartis (NVS) is in talks to buy Avidity Biosciences (RNA) for more than $70 per share. According to @CNBC, the report did not disclose a definitive agreement or timeline, and the coverage did not mention any direct cryptocurrency market impact.